Patents Assigned to Board of Regents of the University of Texas System
  • Publication number: 20240336699
    Abstract: Provided herein are chimeric antigen receptors (CARs) comprising a truncated EGFRvIII (Ev3) in the hinge region of the CAR and/or a humanized scFv. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of immune disorders.
    Type: Application
    Filed: June 21, 2024
    Publication date: October 10, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Sonny Oon ANG, Enli LIU, Elizabeth SHPALL, Katy REZVANI
  • Publication number: 20240336622
    Abstract: Disclosed herein are compounds of the formula (I) or (II) wherein the variables are defined herein. Also provided are methods of manufacturing and pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as PARP1 inhibitors. In some aspects, the present disclosure provides methods wherein the compounds and compositions described herein are used for the treatment of diseases and disorders, such as cancer.
    Type: Application
    Filed: January 8, 2022
    Publication date: October 10, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Yonghao YU, Tian QIN, Yuanli ZHEN, Peng LI, Chiho KIM, Heping DENG, Hejun DENG
  • Publication number: 20240341111
    Abstract: Systems and methods for an active emissive layer configured for use in an electroluminescent device. The active emissive layer includes a host-guest blend in which the host includes a perovskite (e.g., CsPbBr3, CsPbCl3, and/or CsPbI3) and the guest includes quantum shells (QSs) embedded in the host. The QSs include a quantum-confined, spheroidal shell that is a first semiconductor (e.g., CdSe) sandwiched between a core and an outer layer that are a wider band gap semiconductor (e.g., CdS). The active emissive layer is formed by mixing a perovskite solution with a colloid to generate a blended mixture, where the colloid is the QSs suspended in a same solvent used for the perovskite solution. The perovskite solution is coated on a substrate to form a film that is then annealed, and electrodes are formed to flow a current through the active emissive layer, causing emitted light.
    Type: Application
    Filed: April 10, 2024
    Publication date: October 10, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jason D. Slinker, Aditya Kumar Mishra, Anton V. Malko
  • Patent number: 12109349
    Abstract: The present disclosure includes methods, apparatuses, and systems for aspirating an airway of a patient. The apparatuses include a main body having a pump and a storage canister housing coupled to the main body and containing a storage container that is at least partially collapsible. In some configurations, the main body can include a pressure sensor, a controller in communication with the pressure sensor, and having a processor, a memory, and a power source in communication with the controller. The storage canister housing can include a first end coupled to the main body, and a second end having a weighted portion and configured to be coupled to the first end to permit free rotation, such that the second end gravitationally rotates.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: October 8, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Forhad Akhter, Austin R. Schoppe, Omar Navarro, Bruce Adams, Yusheng Feng, Robert Delorenzo, Robert L. Hood
  • Patent number: 12109152
    Abstract: The present disclosure provides a removable eyewear shielding device, an eyewear comprising a removable eyewear shielding device, and methods of uses thereof for reducing eye radiation exposure, reducing ipsilateral brain radiation exposure, reducing FGI-induced lens opacification, reducing cataract development, or protecting an eye or ipsilateral brain from radiation exposure.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: October 8, 2024
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Melissa Kirkwood, Jeffrey Guild, Gary Arbique
  • Patent number: 12109329
    Abstract: The approach described herein uses the spatially and temporally controlled growth for programming 3D shapes and their motions, possibly with an unlimited number of degrees of freedom, could thus create dynamic 3D structures. The ability to program growth-induced 3D shapes and motions could transform the way engineering systems, such as robots, actuators, and artificial muscles, are designed. The concept is applicable to other programmable materials. The 2D printing approach for 3D material programming represents a scalable and customizable 3D manufacturing technology, which can potentially be integrated with biological systems and existing 2D fabrication methods and devices for broader applications.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: October 8, 2024
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Kyung Suk Yum, Amirali Nojoomi
  • Publication number: 20240325444
    Abstract: Embodiments of the disclosure include methods and compositions related to targeting of TROP-2-expressing cells with particular engineered receptors. In specific embodiments, NK cells are specifically engineered to bind TROP-2 using particular chimeric antigen receptor constructs. In certain embodiments, vectors that express the TROP-2-targeting CARs also express a particular suicide gene and/or one or more particular cytokines.
    Type: Application
    Filed: July 8, 2022
    Publication date: October 3, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Katy REZVANI, Sunil ACHARYA, Funda MERIC-BERNSTAM, Nadima UPRETY, Rafet BASAR, David MARIN COSTA
  • Publication number: 20240325443
    Abstract: Embodiments of the disclosure include methods and compositions in which NK cells are modified by the hand of man to express the T-cell receptor and CD3 co-receptor on NK cells that do not naturally express them. Such modified NK cells work effectively with bispecific or multi-specific antibodies that are tailored to comprise anti-CD3 antibodies that bind the modified NK cells, thereby triggering signaling, activation, and cytotoxicity of target cells to which the antibodies also bind. Thus, the NK cells are specifically configured to be able to work effectively with Bispecific NK cell engagers (BiKEs) as well as Bispecific T cell Engagers (BiTEs).
    Type: Application
    Filed: July 22, 2022
    Publication date: October 3, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Enli LIU, Katy REZVANI, Rafet BASAR, Bin LIU, David MARIN COSTA
  • Publication number: 20240325383
    Abstract: Embodiments are directed to molecules for the treatment of Coronavirus infection, including SARS-COV-2 infection. In certain aspects the small molecule is administered via inhalation and/or intranasal administration.
    Type: Application
    Filed: March 22, 2024
    Publication date: October 3, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: Alexander Bukreyev, Jia Zhou
  • Publication number: 20240328040
    Abstract: Sheath-run artificial muscles (or SRAMs) are described in which the dimensional changes and/or modulus changes of a sheath on the surface of a twisted or coiled host yarn or fiber drives torsional and tensile actuation. The sheath-core artificial muscle includes a sheath on a coiled core yarn or fiber that has inserted twist, in which the sheath does not include a yam, the coiled core yarn or fiber includes a core yarn or fiber, the sheath can change volume, modulus, or a combination thereof when actuated by an influence source to drive actuation, and the influence source is selected from a group consisting of absorption processes, desorption processes, changes in temperature, changes in external pressure, changes in a magnetic field, changes in an electric field, exposures to actinic radiation, electrochemical charge and discharge, chemical reactions, and combinations thereof.
    Type: Application
    Filed: June 6, 2024
    Publication date: October 3, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: Ray H. Baughman, Jiuke Mu, Monica Jung De Andrade, Shaoli Fang, Na Li, Carter S. Haines
  • Publication number: 20240325454
    Abstract: Disclosures herein are directed to compositions comprising single guide RNA (sgRNA) designed for a CRISPR/Cas9 system and method of using thereof for preventing, ameliorating or treating one or more cardiomyopathies. For example, provided herein are composition and methods for the correction of dilated cardiomyopathy by precise genomic editing of RBM20 mutations in human cells and mice.
    Type: Application
    Filed: June 30, 2022
    Publication date: October 3, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Eric N. OLSON, Rhonda BASSEL-DUBY, Takahiko NISHIYAMA
  • Publication number: 20240325315
    Abstract: In some aspects, the present disclosure provides compositions of lipid nanoparticles useful for the delivery of large RNAs including mRNAs. These compositions may include a cationic ionizable lipid, a phospholipid, a PEGylated lipid, and a steroid including using less of a cationic ionizable lipid than compositions with shorter nucleic acids. These compositions may be used to treat a disease or disorder for which the delivery of an mRNA is therapeutically effective.
    Type: Application
    Filed: June 14, 2024
    Publication date: October 3, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Daniel J. SIEGWART, Qiang CHENG
  • Publication number: 20240331837
    Abstract: Embodiments of the disclosure concern systems, methods, and compositions related to identification of a suitable cell therapy for an individual in need thereof. A cell line is selected from a plurality of cell lines for suitability for an individual based on an algorithm and cell identification number that includes values for HLA matching and the frequency of reactive CD4 and CD8 cytotoxic T lymphocytes as measured by interferon-? and IL-2. Particular parameters for HLA matching and reactive frequencies are utilized to calculate points towards the cell identification number, and the cell line with the highest cell identification number may be utilized.
    Type: Application
    Filed: July 20, 2022
    Publication date: October 3, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Katy REZVANI, David MARIN COSTA, Elizabeth J. SHPALL
  • Publication number: 20240325456
    Abstract: Multipotent lung progenitor cells for lung regeneration are provided. Accordingly, there are provided methods of expanding in culture an isolated population of pulmonary cells, methods of qualifying suitability of an isolated population of pulmonary cells for administration to a subject in need thereof, and methods of generating an isolated population of pulmonary cells comprising selecting a cell population being double positive for expression of epithelial and endothelial cell markers. Also provided are isolated populations of pulmonary cells, pharmaceutical compositions comprising same and uses of same.
    Type: Application
    Filed: June 7, 2024
    Publication date: October 3, 2024
    Applicants: Yeda Research and Development Co. Ltd., Board of Regents, The University of Texas System
    Inventors: Yair REISNER, Chava ROSEN, Elias SHEZEN, Ran ORGAD, Irit MILMAN KRENTSIS, Xiaohua SU, Raj Kumar YADAV, Yangxi ZHENG
  • Patent number: 12104181
    Abstract: Embodiments of the instant disclosure relate to novel antiviral compositions and methods for treating viral infections. In accordance with these embodiments, antiviral compositions can include at least one mRNA encoding for a TRIM7 protein encapsulated into a lipid nanoparticle (LNP). In other embodiments, methods of making antiviral compositions are disclosed as well as methods of administering a composition having at least one mRNA encoding for a TRIM7 protein encapsulated into LNP into a subject.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: October 1, 2024
    Assignee: The Board of Regents of The University of Texas System
    Inventors: John W. Schoggins, Wenchun Fan, Daniel J. Siegwart, Qiang Cheng
  • Patent number: 12102313
    Abstract: A surgical retractor assembly for providing surgical exposure. The surgical retractor assembly consists of two frame segments connected by adjustable ratchet mechanisms to form a retractor frame. The ratchet mechanisms can be attached to tissue retractor blades that provide exposure of the wound when expanded, without the requirement of a direct connection/attachment to an operating table or bed frame. The tissue retractor blades are attached in a manner that is adjustable and facilitates the ability of the overall surgical retractor assembly to be raised or lowered with respect to the patient. The retractor frame also allows attachments of additional retractor blades or other surgical retractor accessories for additional surgical exposure.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: October 1, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Ramon Francisco Cestero, Justin Alexander Long, Clarence Lamar Long, Jeffrey Adam Long
  • Publication number: 20240317810
    Abstract: Provided herein are chimeric hMPV/RSV F proteins. In some aspects, the chimeric hMPV/RSV F proteins exhibit enhanced conformational stability, enhanced thermostability, and/or increased expression. Methods are also provided for use of the chimeric F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.
    Type: Application
    Filed: July 15, 2022
    Publication date: September 26, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jason MCLELLAN, Ching-Lin HSIEH
  • Publication number: 20240318198
    Abstract: The present disclosure provides methods and compositions for the treatment of Angelman Syndrome The methods and compositions of the present disclosure comprise isolated nucleic acid molecules, rAAV vectors and rAAV viral vectors comprising polynucleotide sequences encoding for short hairpin RNA (shRNA) molecules directed against UBE3A-ATS.
    Type: Application
    Filed: February 2, 2022
    Publication date: September 26, 2024
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Ryan BUTLER, Steven J. GRAY, Hye Ri KANG, Berge A. MINASSIAN, Emrah GUMUSGOZ
  • Publication number: 20240318535
    Abstract: Aspects of the subject technology relate to systems and methods of controlling a drill string having a steerable bit when drilling a wellbore through a substrate. A deterministic model of a directional behavior of the drill string is developed that includes a drill string state, one or more drill parameters associated with the drill string, and one or more substrate parameters associated with the substrate. A stochastic differential model of the directional behavior of the drill string is then developed by replacing the state and each of the parameters of the deterministic model with respective probability distributions and adding feedback. The stochastic differential model is reduced to a truncated stochastic model by substituting a predetermined number of terms of a generalized polynomial chaos expansion for each probability distribution and then evaluating the expectations.
    Type: Application
    Filed: March 23, 2023
    Publication date: September 26, 2024
    Applicants: Halliburton Energy Services, Inc., Board of Regents, The University of Texas System
    Inventors: Nazli DEMIRER, Robert P. DARBE, Alexander Mathew KELLER, Dongmei CHEN
  • Patent number: 12098138
    Abstract: Disclosed herein are compounds of the formula: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. The compounds and compositions provided herein may be used for the treatment or prevention of diseases or disorders, including but not limited to cancer (e.g., pancreatic cancer), including drug-resistant cancers, such as gemcitabine-resistant pancreatic cancer or KRAS dependent tumors.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: September 24, 2024
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Debasish Bandyopadhyay